Status:
COMPLETED
Study of [S,S]-Reboxetine in Patients With Postherpetic Neuralgia, Who Are Gabapentin Treatment Failures
Lead Sponsor:
Pfizer
Conditions:
Pain
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the effectiveness of \[S,S\]-Reboxetine in the treatment of chronic pain following a shingles infection in patients who are Gabapentin treatment failures.
Eligibility Criteria
Inclusion
- Patients must have pain present for more than 3 months after the healing of shingles skin rash.
- Patients at screening must have a score \> or = 40 mm on the pain visual analogue scale.
Exclusion
- Patients with poor renal function.
- Patients with other severe pain, that may impair the self-assessment of the pain due to shingles.
- Patients with abnormal electrocardiogram.
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
End Date :
October 1 2004
Estimated Enrollment :
184 Patients enrolled
Trial Details
Trial ID
NCT00143442
Start Date
December 1 2003
End Date
October 1 2004
Last Update
August 8 2006
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.